RCT | Camrelizumab-rivoceranib outperforms sorafenib as first-line therapy for unresectable HCC

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

New @TheLancet – Qin et al – Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyhttps://t.co/YoutfY5IkA#LiverTwitter #OncTwitter #LiverCancer #HCC pic.twitter.com/Tcvm6D3kCW

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 25, 2023